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Ribosomea b s t r a c t
PIH1D1 is the deﬁning component of the R2TP complex. Recently, R2TP has been reported to stabi-
lize mTOR (mammalian target of rapamycin), an important regulator of cell growth and protein syn-
thesis. Two complexes of mTOR, mTORC1 and mTORC2, have been identiﬁed. We demonstrate that
immunoprecipitation (IP) of PIH1D1 results in the co-IP of Raptor (mTORC1 speciﬁc), but not Rictor
(mTORC2 speciﬁc), and that knockdown of PIH1D1 decreases mTORC1 assembly, S6 kinase phos-
phorylation (indicator of mTORC1 activity), and rRNA transcription without affecting mTORC2 in
human breast cancer MCF-7 cells. In addition, we provide evidence that PIH1D1 is overexpressed
in various breast cancer cell lines. These ﬁndings collectively suggest that PIH1D1 may have an
important role in mTORC1 regulation in breast cancers.
Structured summary of protein interactions:
mTOR physically interacts with PIH1D1 and Raptor by anti tag coimmunoprecipitation (View interac-
tion)
Rictor physically interacts with mTOR and Tel2 by anti bait coimmunoprecipitation (View interaction)
Raptor physically interacts with Tel2, PIH1D1 and mTOR by anti bait coimmunoprecipitation (View
interaction)
PIH1D1 physically interacts with mTOR and Raptor by anti bait coimmunoprecipitation (View
interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mammalian target of rapamycin (mTOR) is a member of the
phosphatidylinositol 3-kinase-related protein kinase (PIKK) family,
which also includes ATM (ataxia telangiectasia mutated), ATR
(ATM- and Rad3-related), DNA-dependent protein kinase catalytic
subunit (DNA-PKcs), suppressor with morphological effect on
genitalia 1 (SMG-1), and TRRAP (transformation/transcription do-
main-associated protein) [1]. mTOR functions within two distinct
multi-subunit complexes, mTOR complex 1 and mTOR complex 2
(mTORC1 and mTORC2, respectively) [2]. mTORC1 consists of
mTOR, mLST8 (also known as GbL) and Raptor. mTORC2 also con-
tains mTOR and mLST8 but, instead of Raptor, it contains Rictor.mTORC1 controls cell growth and protein synthesis by S6 kinase
(S6K), via its ability to phosphorylate multiple substrates including
S6 and eIF4B, whereas mTORC2 regulates cell survival by phos-
phorylating downstream effector Akt. Recently, Tel2 (telomere
maintenance 2) has been identiﬁed to interact with all known
mammalian PIKKs and essentially regulate their abundance [3].
The R2TP complex, identiﬁed in yeast by systematic proteomic
and genomic approaches, is a multi-subunit Hsp90 interacting
complex formed by Rvb1, Rvb2, Tah1, and Pih1 [4–7]. It has been
reported that PIKK family including mTOR is stabilized by Tel2–
R2TP complex [8,9]. We have reported that Monad and its binding
proteins, R2TP complex, regulate apoptosis [10–16]. Among the
components of R2TP complex, Pih1 (PIH1D1 in human) directly
binds to Tel2 [9] and shown to be unstable [6,7,15], raising the pos-
sibility that PIH1D1 may be a critical regulator of R2TP complex.
We have reported that PIH1D1 possesses cell protective function
against apoptosis in human osteosarcoma U2OS cells [13], how-
ever, the mechanism has not been fully explored. Rvb1 and Rvb2
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sed in several cancers including hepatocellular carcinoma, colon
and bladder cancer, and melanoma; they are potential targets for
cancer therapy [17–21]. The role of PIH1D1 in cancer has not been
clariﬁed.
Ribosome biogenesis is likely to be a critical process dysregu-
lated in cancer. mTORC1 regulates the synthesis of ribosomal
components, including transcription and processing of ribosome
RNA (rRNA) and expression of ribosomal proteins [22]. RNA
polymerase (Pol) I transcribes a single 47S rRNA precursor, which
is processed into 18S, 5.8S and 28S rRNA. Mayer et al., showed that
the mTOR–S6K pathway activates the regulatory element tripartite
motif-containing protein-24, which promotes its interaction with
Pol I and the expression of rRNA [23]. By contrast, the
mTOR–S6K axis has also been shown to control rRNA expression
by promoting the interaction of upstream binding factor with
SL1, an event that facilitates Pol I activation [24]. Since PIH1D1 is
reported to be involved in rRNA transcription [25], the role of
PIH1D1 in mTOR-regulated rRNA transcription is worth
investigating.
In this study, we provide evidence that PIH1D1 is overexpressed
in various breast cancer cells and interacts with mTORC1, but not
mTORC2 in human breast cancer MCF-7 cells. We also present a
data showing that PIH1D1 positively regulates mTORC1-depen-
dent rRNA transcription.
2. Materials and methods
2.1. Reagents and antibodies
Anti-PIH1D1 antibody was from Santa Cruz Biotechnology.
Anti-mTOR, anti-GbL, anti-Raptor (24C12), anti-Rictor (D16H9),
anti-p70 S6K, anti-Phospho-S6K (Thr389), anti-Akt, or anti-Phos-
pho-Akt (Ser-473) antibody was from Cell Signaling Technology.
Anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase,
23040091) antibody was from Chemicon. Anti-Tel2 antibody was
generous gift from Dr. de Lange and Dr. Takai (The Rockefeller Uni-
versity). Anti-RPAP3 antibody and anti-Flag antibody (M2) were
from Sigma. Rapamycin was from Calbiochem. Flag-mTOR vector
was generous gift from Dr. Mizushima (Tokyo University) and de-
scribed previously [26].
2.2. Cell Culture
Breast cancer cell lines (MDA-MB-231, SKBr, BT549, MDA-MB-
231, T47, and MCF-7) were obtained from the American Type
Culture Collection. Breast cancer cell lines and HEK293 cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium supplemented
with 10% fetal bovine serum containing 100 lg/ml streptomycin,
100 IU/ml penicillin and 1 ll/ml amphotericin B. Normal human
mammary epithelial cell line was obtained from Lonza and
cultured according to manufacturer’s instructions.
2.3. Transfection and immunoblotting
HEK293 cells were seeded onto 60-mm Petri dishes and grown
for 24 h. Indicated plasmids were transfected with Lipofectamine
2000 according to manufacturer’s instructions (Invitrogen). After
4 h-transfection, the cells were returned to growth medium and
incubated for 48 h. Cells were lysed in extraction buffer (0.3%
CHAPS, 120 mM NaCl, 5 mM EDTA, 10% glycerol, and 20 mM Tris,
pH 7.4) including protease inhibitor cocktail (Roche). Total protein
was mixed with Laemmli denaturing buffer, separated by SDS–
PAGE and transferred to PVDF membranes (Millipore Corporation).
Immunoblotting was carried out as described previously [27].2.4. Immunoprecipitation (IP)
IP was carried out as described previously [28]. Brieﬂy, equal
protein concentrations of lysates were incubated with A/G agarose
beads (Pierce) precoated with indicated antibody or normal mouse
or rabbit IgG (Santa Cruz). Associated proteins were recovered by
boiling in Laemmli buffer.
2.5. Knockdown experiments
Tel2 or PIH1D1-speciﬁc siRNA was purchased from Qiagen and
targeted the following sequences: 50-CAGGGCACGGGCTCTCA
GAAA-30 or 50-CCTACGACGTAGCTGTCAATT-30 (target-1); 50-CCCGC
TGCAGATCAACTCTCA-30 (target-2) and transfected with Lipofect-
amine RNAiMAX according to the manufacturer’s instructions
(Invitrogen). AllStars Negative Control siRNA (Qiagen) was used
as a control.
2.6. Lentiviral transduction and establishment of stable cell line
The siRNA-resistant PIH1D1 was cloned into pENTR/D TOPO
and subcloned into pLenti6.3/V5-DEST using Gateway System
(Invitrogen). This vector or pLenti3.3/TR was cotransfected into
293FT cells with ViraPower packaging mix (Invitrogen) to generate
the lentivirus according to the manufacturer’s protocol. MCF-7
cells were transduced with the lentivirus and stable cell lines were
generated by selecting with geneticin (pLenti3.3/TR) or blasticidin
(pLenti6.3/V5-DEST), respectively. Silent mutations (indicated by
bold/italic letters) that were introduced are 50-CCCCTGCAGAT
AAATTCCCA-30. Site-directed mutagenesis was performed using
the QuikChange II Site-directed Mutagenesis Kit (Agilent Technol-
ogies) and all mutations were conﬁrmed by sequencing.
2.7. Quantitative RT-PCR for pre-rRNA synthesis
Quantitative RT-PCR (RT-qPCR) was performed as previously
described [28]. The relative expression of pre-rRNA was normal-
ized to b-actin using the comparative CT method. Speciﬁc primers
for pre-rRNA (forward: 50-GAACGG TGGTGTGTCGTTC-30; reverse:
50-GCGTCTCGTCTCGTCTCACT-30) and b-actin (forward: 50-ATCGTC-
CACCGCAAATGCTTCTA-30; reverse: 50-AGCCATGCCAATCTCATC
TTGTT-30) were used for PCR ampliﬁcation [29].
2.8. Statistical analysis
Data are expressed as mean ± S.E.M. Statistical differences be-
tween groups were determined using Tukey test after ANOVA.
3. Results
3.1. Expression of PIH1D1 in breast cancer cell lines
We analyzed PIH1D1 expression using anti-PIH1D1 antibody
and found that PIH1D1 is highly expressed in various human
breast cancer cell lines (Fig. 1). On the other hand, PIH1D1 expres-
sion was low in normal human mammary epithelial cells (HMEC)
and human breast cancer BT549 cells (Fig. 1). RPAP3 expression
was not different between normal and cancer cells (Fig. 1).
3.2. PIH1D1 interacts with mTORC1
Previous studies have demonstrated that mTOR interaction
with Raptor and Rictor is disrupted when cells are lysed with 1%
Triton X-100-containing buffer, but not with 0.3% CHAPS-contain-
ing buffer [30]. When we transfected HEK293 cells with Flag-mTOR
Fig. 1. PIH1D1 expression in breast cancer cell lines. Lysates from breast cancer cell
lines were subjected to SDS–PAGE followed by immunoblotting with anti-PIH1D1,
RPAP3, or GAPDH antibody. A given immunoblot is a representative of three
independent experiments.
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ing buffer but was disrupted in Triton X-100-containing buffer
(Fig. 2A). We thus used the CHAPS-containing buffer in the IP
experiments. The endogenous interaction between mTOR and
PIH1D1 in human breast cancer MCF-7 cells was also detected by
IP using an antibody against PIH1D1, suggesting that their interac-
tion is physiologically relevant (Fig. 2B). We also investigated the
endogenous interaction between PIH1D1 and either Raptor (spe-
ciﬁc for mTORC1) or Rictor (speciﬁc for mTORC2) and found that
PIH1D1 interacted with Raptor, but not Rictor in MCF-7 cells
(Fig. 2B and C). As reported previously [3], Tel2 was present both
in mTORC1 and mTORC2 (Fig. 2C).A
B C
Fig. 2. PIH1D1 interacts with mTORC1. (A) HEK293 cells were transfected with an em
containing either 0.3% CHAPS or 1% Triton X-100. IP was then performed with anti-Flag
antibodies or normal mouse IgG (B) or anti-Raptor, anti-Rictor antibodies, or normal rabb
of three independent experiments.3.3. PIH1D1 regulates mTORC1 activity
mTORC1 can phosphorylate S6K, whereas mTORC2 phosphory-
lates AKT [2]. We analyzed whether PIH1D1 regulates the activity
of mTORC1 and mTORC2. Small interfering RNA (siRNA)-mediated
knockdown of PIH1D1 was very effective and reduced PIH1D1
expression to almost undetectable levels in MCF-7 cells (Fig. 3A).
In these cells, mTOR expression levels were not changed. Knock-
down of PIH1D1 suppressed the phosphorylation of S6K without
affecting the amount of S6K. To rule out off-target effects of siRNA,
we used a rescue strategy. We established doxycycline (DOX)-reg-
ulatable MCF-7 cells overexpressing PIH1D1 and introduced si-
lence mutations in the target sequence of siRNA and made the
mRNA insensitive to siRNA. As shown in Fig. 3C, induced overex-
pression of PIH1D1 by DOX rescued inhibitory effect of PIH1D1 siR-
NA on the phosphorylation of S6K without affecting the amount of
S6K. These results, together with the data that PIH1D1 interacts
with mTORC1, suggest that PIH1D1 positively regulates mTORC1
activity. Next, we analyzed the involvement of PIH1D1 in mTORC2
regulation. The phosphorylation of Akt at Ser-473, which is a well
known indicator of mTORC2 activity was not changed in cells trea-
ted with PIH1D1 siRNA (Fig. 3A), suggesting that PIH1D1 is not
important for mTORC2 activity. In contrast, in Tel2-knockdown
cells, the phosphorylation of S6K and Akt was inhibited (Fig. 3B),
as reported previously [3]. Also, mTOR expression levels were de-
creased in Tel2-knockdown cells (Fig. 3B), consistent with previous
report [3].
3.4. PIH1D1 is important for mTORC1 assembly
Decreased mTORC1 activity was clearly observed even when
mTOR protein levels were not changed following knockdown of
PIH1D1 (Fig. 3A). It has been reported that Tel2–R2TP complexpty vector or Flag-mTOR. After 48 h, cells were harvested and lysed in a buffer
antibody. (B and C) MCF-7 cells were lysed and IP was performed with anti-PIH1D1
it IgG (C) to detect endogenous interactions. A given immunoblot is a representative
A B
C D
Fig. 3. PIH1D1 potentiates mTORC1 activity. MCF-7 cells were transfected with PIH1D1 (A) or Tel2 (B) siRNA in serum free conditions and after 48 h, the phosphorylation of
S6K and Akt was examined by immunoblotting following 2 h serum treatment. (C) MCF-7 cells overexpressing DOX-regulatable and siRNA-resistant PIH1D1 were transfected
with PIH1D1 siRNA. The phosphorylation of S6K was analyzed by immunoblotting at 48 h after the treatment with PIH1D1 siRNA. (D) MCF-7 cells were transfected for 48 h
with PIH1D1 siRNA and the assembly of mTORC1 (the interaction of GbL and Raptor) or mTORC2 (the interaction of GbL and Rictor) was determined by immunoblotting.
A given immunoblot is a representative of three independent experiments.
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mTOR (Fig. 3B), these observations prompted us to hypothesize that
PIH1D1 might have functions other than the stabilization of mTOR
protein to regulate mTORC1 activity. One possibility was that
PIH1D1 facilitates mTOR complex formation. We tested this possi-
bility by immunoprecipitating the mTOR complex. Knockdown of
PIH1D1 did not affect the levels of GbL and Raptor in MCF-7 cells,
but decreased the amount of GbL in the Raptor immunoprecipi-
tates, while the amount of GbL in the Rictor immunoprecipitates
was not changed (Fig. 3D). This suggests that mTORC1, but not
mTORC2, is partially disassembled in PIH1D1-depleted cells.
3.5. PIH1D1 regulates rRNA transcription
It has been reported that PIH1 is a positive regulator in the
transcription of rRNA genes [25]. mTORC1 is a major regulator of
ribosomal biogenesis and protein synthesis. The lack of S6K
phosphorylation in PIH1D1-silenced cells prompted us to examine
whether PIH1D1 silencing can inhibit rRNA transcription. Three of
the rRNAs, 5.8S, 18S and 28S, are transcribed as a single precursor,
47S pre-rRNA, by Pol I in the nucleolus, which is then processed
through several steps to generate the mature rRNAs. We measured
the level of the pre-rRNA in MCF-7 cells, and found that knock-
down of PIH1D1 decreases rRNA level (Fig. 4A). When rapamycin
(20 nM) was added, no further inhibitory effect of PIH1D1 silencing
on rRNA level was observed (Fig. 4A), suggesting that the effect of
PIH1D1 is mTOR-dependent.4. Discussion
Increased protein synthesis and cell growth are critical for
tumorigenesis. Tumor cells are generally larger than normal cells
and contain more and bigger nucleoli, a phenotype indicative of in-
creased ribosome synthesis [31,32]. mTORC1 signaling plays an
essential role in cancer [2], and gain of function of this pathway
has been demonstrated in various cancers. Multiple components
of this pathway are either oncogenes or tumor suppressors.
mTORC1 coordinates the synthesis of both ribosomal proteins
and rRNA to modulate ribosome biogenesis [22–24]. These obser-
vations thus indicate that control of ribosome biogenesis through
mTORC1 pathway is critical for tumorigenesis.
It has been reported that PIKK family including mTOR is
stabilized by Tel2–R2TP complex [8,9]. However, the precise mech-
anism has not been explored. We ﬁrst questioned which mTOR
complex contains PIH1D1. Importantly, PIH1D1 was detected in
Raptor immunoprecipitates, but not in Rictor immunoprecipitates,
suggesting that PIH1D1 speciﬁcally targets mTORC1. As reported
previously [3], Tel2 was detected in both complexes. We also
detected Raptor and mTOR, but not Rictor in PIH1D1 immunopre-
cipitates. These results indicate that PIH1D1 is mTORC1-speciﬁc
protein. We also demonstrated that PIH1D1 regulates mTORC1,
but not mTORC2 activity. It has been reported that mTORC2 activ-
ity is negatively modulated by feedback inhibition of mTORC1 [2].
We conﬁrmed that by rapamycin treatment, which inhibits
mTORC1 activity, Akt phosphorylation in MCF-7 is up-regulated
AB
Fig. 4. (A) Knockdown of PIH1D1 decreases pre-rRNA levels. MCF-7 cells were transfected with PIH1D1 siRNA in the presence or absence of rapamycin (Rapa, 20 nM), and
pre-rRNA levels were determined after 48 h by RT-qPCR. Values are means ± S.E.M. from four independent experiments. Data were normalized based on b-actin mRNA copy
numbers. ⁄P < 0.01 vs control in the absence of rapamycin. (B) Possible targets of PIH1D1. PIH1D1 could modulate ribosome biogenesis at multiple steps, by affecting mTORC1
(I), rRNA transcription (II), or rRNA processing (III). See text for details.
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nism by which negative feedback effect on mTORC2 is canceled in
PIH1D1-depleted cells is unclear, it is interesting to note that sim-
ilar phenomena have been recently reported [33]. Further investi-
gation is needed for the elucidation of the mechanism by which
PIH1D1 selectively inﬂuences on mTORC1.mTOR controls ribosome
biogenesis by at least two mechanisms: by promoting the transla-
tion of mRNAs for ribosomal proteins and by affecting rRNA syn-
thesis. We showed that pre-rRNA transcription is positively
regulated by PIH1D1, and this is consistent with previous report
by Zhai et al., [25]. They focused on silencing nucleolar remodeling
complex (NoRC) and found that PIH1D1 is involved in the dere-
pression of NoRC-silenced rRNA genes [25]. Since pre-rRNA tran-
scription is enhanced by mTOR [34], based on our new ﬁndings,
we propose that the effect of PIH1D1 on pre-rRNA transcription
could be mTOR-dependent (Fig. 4B). Regarding the effect of PIH1D1
on rRNA transcription, it is possible that both mTOR-dependent
and -independent mechanisms exist. It has been also reported that
pre-rRNA processing is regulated by R2TP complex [7]. Interest-
ingly, mTOR, PIH1D1, and another component of R2TP complex,
Rvb1 (pontin in human) are localized in nucleoli [34–36].
PIH1D1 is known to be an unstable protein [7], and we have re-
ported that PIH1D1 is stabilized by another component of R2TP
complex, Tah1 (RPAP3 in human) [15]. In this study, we showedthat PIH1D1 is overexpressed in breast cancers. However, overex-
pression of RPAP3 was not observed in breast cancer cells, suggest-
ing that another mechanism exists by which PIH1D1 is stabilized.
Using comprehensive meta-analysis of The Cancer Genome Atlas
data sets, Kim et al. found that the expression of many R2TP com-
plex mRNA was signiﬁcantly higher in breast carcinomas when
compared to their normal tissue controls [37]. They hypothesized
that elevated expression of R2TP complex promotes mTORC1 sig-
naling and metabolic process that are necessary for tumor cell
growth. mTORC1 is an important regulators of not only ribosome
biogenesis and metabolic process, but also cell survival. Choi
et al., has recently reported that inhibition of S6K enhances glucose
deprivation-induced cell death in MCF-7 cells [38]. In this study,
knockdown of PIH1D1 in MCF-7 cells did not affect both Akt,
well-known regulator of cell survival (Fig. 3A) and cell survival rate
estimated by MTT assay (data not shown). The role of R2TP com-
plex and PIH1D1 in cell survival awaits further investigation.
Clearly, the data presented here along with the recent studies
describing the role of Tel2–R2TP complex onmTORC1 [39–41] dem-
onstrate thatmTORC1 is a direct target for PIH1D1. Considering that
mTORC1 has been proposed as a promising target for cancer treat-
ment [2], understanding PIH1D1–mTORC1 axis in breast cancer
may lead to the development of additional targeted agents to sup-
press this axis, and result in improved treatments for breast cancer.
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